Many biotech firms find themselves in the unenviable position of having innovative
products to shout about, but FDA regulations force them to keep mum
It was only three years ago that La Jolla, CA-based biotech company Ambrx was a few scientists and an idea. Now in 2006, it is a full-fledged biopharmaceutical firm with more than 50 employees; a new CEO, Martin Mattingly, formerly of CancerVax; and a mission to deliver breakthrough protein therapeutics.
It wasn't a short path, but Mattingly understood that ...